MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
MannKind completed patient randomization in its U.S. Phase 1b INFLO-1 study for nintedanib DPI in IPF patients and enrolled the first patient in the global Phase 2 INFLO-2 trial. The company expects to report Phase 1b data in Q3 2026, which will provide initial safety, tolerability, and pharmacokinetic assessments.
Key figures
- Drug Name
- nintedanib DPI (MNKD-201)
- Phase Of Trial
- Phase 2
- Inflo 2 sites
- 85
- Inflo 1 data readout
- Q3 2026
- Inflo 2 enrollment target
- 210
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.